Biogen Preliminary Third Quarter 2026 Acquired In-Process Research and Development Charges

Cambridge, MA, - - Biogen Inc. (Nasdaq: BIIB) (Biogen) expects that its GAAP and non-GAAP results for the third quarter of 2026 will include acquired in-process research and development, upfront and milestone expense of approximately $284 million on a pre-tax basis. The estimated charge is expected to impact GAAP and non-GAAP net income per diluted share for the third quarter of 2026 by approximately $1.65 and $1.70, respectively.

In addition, Biogen expects approximately $35 million of acquired in-process research and development, upfront and milestone expense originally anticipated to be recorded in the third quarter to be recognized in the fourth quarter.

Acquired in-process research and development, upfront and milestone expense includes costs incurred in connection with collaboration and license agreements such as upfront and milestone payments and, when applicable, premiums on equity securities and asset acquisitions of acquired in-process research and development. Biogen does not forecast such acquired in-process research and development, upfront and milestone expense due to the uncertainty of the future occurrence, magnitude and timing of these transactions in any given period.

Results for the quarter ended September 30, 2026, have not been finalized and are subject to our financial statement closing procedures. There can be no assurance that our final results will not differ from the preliminary unaudited estimates described herein.

About Biogen
Founded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patient's lives and to create value for shareholders and our communities. We apply deep understanding of human biology and leverage different modalities to advance first-in-class treatments or therapies that deliver superior outcomes. Our approach is to take bold risks, balanced with return on investment to deliver long-term growth.

We routinely post information that may be important to investors on our website at www.biogen.com. Follow us on social media - Facebook, LinkedIn, X, YouTube.

Contact:
Karen Jewell
Investor Relations
Biogen
781.464.2442